Skip to content
At-406
At-406 is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against tyrosine-protein kinase SYK, tyrosine-protein kinase Lyn, and tyrosine-protein kinase ABL1. In addition, it is known to target proto-oncogene tyrosine-protein kinase receptor Ret.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell carcinoma of head and neckD000077195—11—13
Head and neck neoplasmsD006258——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8041———4
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Non-small-cell lung carcinomaD0022891————1
Pancreatic neoplasmsD010190EFO_0003860C251————1
AdenocarcinomaD0002301————1
Myeloid leukemia acuteD015470C92.01————1
LymphomaD008223C85.91————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAT-406
INNxevinapant
Description
At-406 is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against tyrosine-protein kinase SYK, tyrosine-protein kinase Lyn, and tyrosine-protein kinase ABL1. In addition, it is known to target proto-oncogene tyrosine-protein kinase receptor Ret.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)CC[C@H]2CC[C@@H](C(=O)NC(c3ccccc3)c3ccccc3)N2C1=O
Identifiers
PDB—
CAS-ID1071992-57-8
RxCUI—
ChEMBL IDCHEMBL2158051
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDN65WC8PXDD (ChemIDplus, GSRS)
Target
Agency Approved
SYK
SYK
LYN
LYN
ABL1
ABL1
Organism
Homo sapiens
Gene name
SYK
Gene synonyms
NCBI Gene ID
6850
Protein name
tyrosine-protein kinase SYK
Protein synonyms
p72-Syk, Spleen tyrosine kinase
Uniprot ID
P43405
Mouse ortholog
Syk (20963)
tyrosine-protein kinase SYK (P48025)
Alternate
RET
RET
Organism
Homo sapiens
Gene name
RET
Gene synonyms
CDHF12, CDHR16, PTC, RET51
NCBI Gene ID
5979
Protein name
proto-oncogene tyrosine-protein kinase receptor Ret
Protein synonyms
Cadherin family member 12, cadherin-related family member 16, Proto-oncogene c-Ret, rearranged during transfection, ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease), RET receptor tyrosine kinase
Uniprot ID
Q9BTB0
Mouse ortholog
Ret (19713)
proto-oncogene tyrosine-protein kinase receptor Ret (P35546)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 87 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5 adverse events reported
View more details